Post-earnings recap
Reported
Wed, May 6, 2026
EPS actual
$4.75
EPS est.
$4.80
EPS surprise
-1.04%
1-day move
-17.38%
Cencora, Inc. reported an EPS of $4.75, slightly missing expectations. The stock reacted negatively, dropping 17.38%, likely due to investor disappointment over the earnings miss and lack of revenue information.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $4.75 | N/A | -1.04% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based on numerical results only.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Cencora, Inc. operates in the health care sector, specifically as a distributor of medical products and services. With a market cap of $59 billion, the company plays a crucial role in ensuring that health care providers have access to necessary supplies, which is vital for patient care and overall health outcomes.
Last quarter
In the last quarter, Cencora reported an EPS of $4.08, slightly beating estimates. However, the stock declined by 8.79% the following day, indicating potential investor concerns despite the earnings beat.
EPS beat streak
1Q
EPS beat rate
88%
Avg EPS surprise
+3.47%
Avg 1-day reaction
-1.56%
Overall, expectations for Cencora's upcoming earnings are mixed, with no analyst estimates available. Investors will be keen to see if the company can maintain its track record of beating EPS estimates.
Bull case
The optimistic view hinges on Cencora continuing its trend of EPS beats, potentially driven by strong demand for health care products and efficient cost management.
Bear case
On the flip side, concerns about rising costs or supply chain issues could lead to disappointing results, especially if revenue growth does not meet expectations.
Key metrics to watch
EPS (Earnings Per Share)
$4.07EPS is a key indicator of profitability and helps investors gauge the company's financial health.
Revenue Growth
N/ARevenue growth reflects the company's ability to expand its business and meet market demand.
The print will turn on these.
Q1
Will Cencora's EPS exceed $4.07?
Given the company's history of beating EPS estimates, this number will be crucial for investor confidence.
Q2
What are the revenue growth figures for this quarter?
Revenue growth is essential for understanding the company's market position and ability to sustain profitability.
Why consensus could be wrong
The Street may be underestimating Cencora's ability to maintain high EPS due to its strong operational efficiencies and market position.
Supporting evidence
Cencora has consistently beaten EPS estimates in the past, indicating strong management performance.
The options market is pricing in a larger move than historical averages, suggesting that investors expect significant news.
Despite recent stock price declines, the company's fundamentals remain strong.
Key risk
If EPS comes in below $4.00, it could lead to a significant reevaluation of the company's growth prospects.
Pre-commit to what would confirm each case.
The market is debating whether Cencora can maintain its profitability amid rising costs and supply chain challenges.
Bull confirmed if
An EPS of $4.10 or higher would confirm the bull case, indicating strong operational performance.
Bear confirmed if
An EPS below $4.00 would confirm the bear case, raising concerns about the company's profitability.
What the market is pricing for the move.
Implied Move
±5.56%
Historical Avg
±5.7%
The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings announcement.
Options are pricing ±6.5% while COR has averaged ±5.7% over the last 8 prints — setup is roughly in line with history.
ATM IV
0.5%
30d HV
21.1%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: X of Y (Z%)
This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.6%, with a raw directional average of +0.8% (modestly positive historical bias).
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$298,935.48
986 sh
1 insider
Net
$298,935.48
Net selling
Most Active Insiders· 1 open-market trade
$298,935.48
Net selling
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Cencora beats expectations and raises guidance, history suggests the stock could react positively, averaging a +0.02% move on beats.
In line / cautious
If the results are in line with expectations but management provides cautious commentary, the stock may see a muted reaction.
Miss
Should the company miss expectations, history indicates a potential downside move, averaging -2.93% on misses.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
0 buys·1 sell
Members
1
House only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Gross Margin
N/AGross margin indicates how efficiently the company is producing its products and managing costs.
Recent Transactions
Oct 1, 2026 · @ $303.18
986 sh
$298,935.48
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Net selling
Recent Transactions
Traded May 6, 2026 · disclosed Jun 19, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.